立即注册 登录
公卫人 返回首页

xiaopang1980的个人空间 https://www.epiman.cn/?2113 [收藏] [复制] [RSS]

日志

小胖说统计之二五四:Longitudinal Data分析的常见方法(七)

热度 107已有 6649 次阅读2010-5-3 22:47 |

MMRM (六)

 

上两篇博文,小胖介绍了observed case anlaysisLOCFMMRM处理缺失值方法的不同,由于其处理缺失值方法的不同,有时会导致结果的大不同,下边我们来看一个这方面的实例:

 

 

Pollack MH,et al.The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.J Clin Psychiatry. 2005 Nov;66(11):1401-8.

 

这是一项评价selective GABA reuptake inhibitor tiagabine治疗成年广泛性焦虑障碍的为期8周的随机双盲安慰剂对照研究。本研究的主要终点是the change from baseline in HAMA total score to final visit

 

Result

 

A total of 266 patients (tiagabine, N = 134; placebo, N = 132) were included in safety analyses; 260 patients (tiagabine N = 130; placebo N = 130) were included in efficacy analyses. Tiagabine reduced symptoms of GAD according to the observed case and mixed models repeated-measures (MMRM) analyses but not the primary last-observation-carried-forward (LOCF) analysis.

 

Conclusion

 

 

The primary LOCF analysis was negative; however, results from the observed case and MMRM analyses suggest that tiagabine may be a useful treatment option for adult patients diagnosed with GAD. These findings warrant further evaluation in randomized clinical studies.

 

从上边这个临床试验的实例中,我们可以看出,试验共进行了三种分析即observed caseLOCFMMRM分析,然而却出现了不同的结论,LOCF分析的结果是阴性的,而observed caseMMRM分析的结果却是阳性的,怎么来解释呢?

 

我们来看一下病人入组和完成试验的情况,下边是本试验的patient disposition情况:

 

(1)      对于observed case分析来说,纳入主要终点分析的病人为两组完成试验的病人数即97100197

(2)      对于LOCF分析来说,纳入主要终点分析的病人为130130260,但两组经过LOCF结转的病人分别为1309733例以及13010030例,共63

(3)      对于MMRM来说,纳入主要终点分析的病人为130130260,并且这260例病人没有一例病人是结转的

 

patient disposition情况来看,其drop out是比较高的,因此经LOCF结转的病例也会比较多,这就为三种分析最后出现不同的结果埋下了伏笔。。。


路过

鸡蛋
6

鲜花

握手

雷人

刚表态过的朋友 (6 人)

发表评论 评论 (1 个评论)

回复 巴尔特同意 2013-3-29 10:29
受教了

facelist

您需要登录后才可以评论 登录 | 立即注册

手机版|会员|至尊|接种|公卫人 ( 沪ICP备06060850号-3 )

GMT+8, 2024-5-16 02:55 , Processed in 0.030256 second(s), 6 queries , Gzip On, MemCached On.

Powered by Discuz! X3.4

© 2001-2023 Discuz! Team.

返回顶部